Small molecule inhibitors of Abeta assembly

References

• Hayden M R, Tyagi S C, Kerklo M M, Nicolls M R. Type 2 diabetes mellitus as a conformational disease. JOP 2005; 6: 287–302
   PubMedGoogle Scholar
• Clark A, Nilsson M R. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes?. Diabetologia 2004; 47: 157–169
   PubMed Web of Science ®Google Scholar
• Hull R L, Westermark G T, Westermark P, Kahn S E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3629–3643
   PubMed Web of Science ®Google Scholar
• Walker L C, LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 2000; 21: 83–95
   PubMed Web of Science ®Google Scholar
• Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: ‘permissive templating’ as a general mechanism underlying neurodegeneration. Biochem Soc Trans 2005; 33: 578–581
   PubMed Web of Science ®Google Scholar
• Dimakopoulos A C. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr Alzheimer Res 2005; 2: 19–28
   PubMedGoogle Scholar
• Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26: 6011–6018
   PubMed Web of Science ®Google Scholar
• Carrell R W. Cell toxicity and conformational disease. Trends Cell Biol 2005; 15: 574–580
   PubMed Web of Science ®Google Scholar
• Lin J C, Liu H L. Protein conformational diseases: from mechanisms to drug designs. Curr Drug Discov Technol 2006; 3: 145–153
   PubMedGoogle Scholar
• Dahlgren K N, Manelli A M, Stine W B, Jr, Baker L K, Krafft G A, LaDu M J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046–32053
   PubMed Web of Science ®Google Scholar
• Walker L C, Bian F, Callahan M J, Lipinski W J, Durham R A, LeVine H. Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?. Amino Acids 2002; 23: 87–93
   PubMed Web of Science ®Google Scholar
• Walker L C, LeVine H. The cerebral proteopathies. Neurobiol Aging 2000; 21: 559–561
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271–278, discussion 278–284
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging 2004; 25: 713–718
   PubMed Web of Science ®Google Scholar
• Williams D R. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 2006; 36: 652–660
   PubMed Web of Science ®Google Scholar
• Lee V M, Kenyon T K, Trojanowski J Q. Transgenic animal models of tauopathies. Biochim Biophys Acta 2005; 1739: 251–259
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Kitazawa M, Tseng B P, LaFerla F M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24: 1063–1070
   PubMed Web of Science ®Google Scholar
• Pickhardt M, von Bergen M, Gazova Z, Hascher A, Biernat J, Mandelkow E M, Mandelkow E. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005; 2: 219–226
   PubMedGoogle Scholar
• Dickey C A, Petrucelli L. Current strategies for the treatment of Alzheimer's disease and other tauopathies. Expert Opin Ther Targets 2006; 10: 665–676
   PubMed Web of Science ®Google Scholar
• Wetzel R. Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res 2006; 39: 671–679
   PubMed Web of Science ®Google Scholar
• Modler A J, Fabian H, Sokolowski F, Lutsch G, Gast K, Damaschun G. Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid 2004; 11: 215–231
   PubMed Web of Science ®Google Scholar
• Modler A J, Gast K, Lutsch G, Damaschun G. Assembly of amyloid protofibrils via critical oligomers – a novel pathway of amyloid formation. J Mol Biol 2003; 325: 135–148
   PubMed Web of Science ®Google Scholar
• Maji S, Bitan G, Vollers S S, Spring S, Condron M M, Teplow D B. Site-specific analysis of abeta oligomerization using photochemical cross-linking. Neurobiol Aging 2004; 25: 163
   Web of Science ®Google Scholar
• Bitan G, Vollers S S, Teplow D B. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003; 278: 34882–34889
   PubMed Web of Science ®Google Scholar
• Bitan G, Kirkitadze M D, Lomakin A, Vollers S S, Benedek G B, Teplow D B. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2003; 100: 330–335
   PubMed Web of Science ®Google Scholar
• Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton A L, Vigouret J M, Paganetti P, Walsh D M, Mathews P M, Ghiso J, Staufenbiel M, Walker L C, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781–1784
   PubMed Web of Science ®Google Scholar
• Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000; 20: 8–22
   PubMed Web of Science ®Google Scholar
• O'Nuallain B, Williams A D, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279: 17490–17499
   PubMed Web of Science ®Google Scholar
• Chen Y R, Glabe C G. Distinct early folding and aggregation properties of alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem 2006; 281: 24414–24422
   PubMed Web of Science ®Google Scholar
• Walsh D M, Tseng B P, Rydel R E, Podlisny M B, Selkoe D J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000; 39: 10831–10839
   PubMed Web of Science ®Google Scholar
• Lesne S, Koh M T, Kotilinek L, Kayed R, Glabe C G, Yang A, Gallagher M, Ashe K H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352–357
   PubMed Web of Science ®Google Scholar
• Petkova A T, Leapman R D, Guo Z, Yau W M, Mattson M P, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005; 307: 262–265
   PubMed Web of Science ®Google Scholar
• Walsh D M, Townsend M, Podlisny M B, Shankar G M, Fadeeva J V, Agnaf O E, Hartley D M, Selkoe D J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 2005; 25: 2455–2462
   PubMed Web of Science ®Google Scholar
• Townsend M, Shankar G M, Mehta T, Walsh D M, Selkoe D J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572: 477–492
   PubMed Web of Science ®Google Scholar
• Bark N, Tjernberg L, Rigler R, Terenius L. Fluorescence burst analysis of cerebrospinal fluid as a diagnostic tool for Alzheimer's disease. 8th International Conference on Alzheimers Disease and Related Disorders, New York, 2002. Elsevier, Abstr 1382
   Google Scholar
• Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998; 4: 832–834
   PubMed Web of Science ®Google Scholar
• Tjernberg L O, Pramanik A, Bjorling S, Thyberg P, Thyberg J, Nordstedt C, Berndt K D, Terenius L, Rigler R. Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. Chem Biol 1999; 6: 53–62
   PubMed Web of Science ®Google Scholar
• Bitan G, Fradinger E A, Spring S M, Teplow D B. Neurotoxic protein oligomers – what you see is not always what you get. Amyloid 2005; 12: 88–95
   PubMed Web of Science ®Google Scholar
• Manning M, Colon W. Structural basis of protein kinetic stability: resistance to sodium dodecyl sulfate suggests a central role for rigidity and a bias toward beta-sheet structure. Biochemistry 2004; 43: 11248–11254
   Google Scholar
• Kayed R, Head E, Thompson J L, McIntire T M, Milton S C, Cotman C W, Glabe C G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486–489
   PubMed Web of Science ®Google Scholar
• Lambert M P, Viola K L, Chromy B A, Chang L, Morgan T E, Yu J, Venton D L, Krafft G A, Finch C E, Klein W L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001; 79: 595–605
   PubMed Web of Science ®Google Scholar
• Chang L, Bakhos L, Wang Z, Venton D L, Klein W L. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci 2003; 20: 305–313
   PubMed Web of Science ®Google Scholar
• Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner R S, Harlan J, Barlow E, Ebert U, Hillen H. Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005; 95: 834–847
   PubMed Web of Science ®Google Scholar
• O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002; 99: 1485–1490
   PubMed Web of Science ®Google Scholar
• Miller D L, Currie J R, Mehta P D, Potempska A, Hwang Y W, Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry 2003; 42: 11682–11692
   PubMed Web of Science ®Google Scholar
• Mastrangelo I A, Ahmed M, Sato T, Liu W, Wang C, Hough P, Smith S O. High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 2006; 358: 106–119
   PubMed Web of Science ®Google Scholar
• El Agnaf O M, Mahil D S, Patel B P, Austen B M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 2000; 273: 1003–1007
   PubMed Web of Science ®Google Scholar
• LeVine H, III. Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors. Anal Biochem 2006; 356: 265–272
   PubMed Web of Science ®Google Scholar
• Bieschke J, Giese A, Schulz Schaeffer W, Zerr I, Poser S, Eigen M, Kretzschmar H. Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 2000; 97: 5468–5473
   PubMed Web of Science ®Google Scholar
• Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377–37382
   PubMed Web of Science ®Google Scholar
• Nakagami Y. Inhibitors of beta-amyloid-induced toxicity by modulating the Akt signaling pathway. Drug News Perspect 2004; 17: 655–660
   PubMedGoogle Scholar
• O'Nuallain B, Thakur A K, Williams A D, Bhattacharyya A M, Chen S, Thiagarajan G, Wetzel R. Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol 2006; 413: 34–74
   PubMed Web of Science ®Google Scholar
• Lomakin A, Chung D S, Benedek G B, Kirschner D A, Teplow D B. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 1996; 93: 1125–1129
   PubMed Web of Science ®Google Scholar
• Jarrett J T, Lansbury P T, Jr. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry 1992; 31: 12345–12352
   PubMed Web of Science ®Google Scholar
• Jarrett J T, Berger E P, Lansbury P T, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693–4697
   PubMed Web of Science ®Google Scholar
• Lansbury P T. Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies. Arzneim Forsch 1995; 45: 432–434
   PubMed Web of Science ®Google Scholar
• Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-{beta}(1-42) fibrils. Proc Natl Acad Sci USA 2005; 102: 17342–17347
   PubMed Web of Science ®Google Scholar
• Balbach J J, Petkova A T, Oyler N A, Antzutkin O N, Gordon D J, Meredith S C, Tycko R. Supramolecular structure in full-length Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance. Biophys J 2002; 83: 1205–1216
   PubMed Web of Science ®Google Scholar
• Nelson R, Sawaya M R, Balbirnie M, Madsen A O, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005; 435: 773–778
   PubMed Web of Science ®Google Scholar
• Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 2006; 16: 260–265
   PubMed Web of Science ®Google Scholar
• Makin O S, Serpell L C. Structures for amyloid fibrils. FEBS J 2005; 272: 5950–5961
   PubMed Web of Science ®Google Scholar
• Serpell L C, Fraser P E, Sunde M. X-ray fiber diffraction of amyloid fibrils. Methods Enzymol 1999; 309: 526–536
   PubMed Web of Science ®Google Scholar
• Paravastu A K, Petkova A T, Tycko R. Polymorphic fibril formation by residues 10-40 of the Alzheimer's {beta}-amyloid peptide. Biophys J 2006; 90: 4618–4629
   PubMed Web of Science ®Google Scholar
• Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006; 409: 215–219
   PubMed Web of Science ®Google Scholar
• Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J P, Vanmechelen E, Sergheraert C, Delacourte A. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003; 85: 1581–1591
   PubMed Web of Science ®Google Scholar
• Klimov D K, Thirumalai D. Dissecting the assembly of abeta(16–22) amyloid peptides into antiparallel beta sheets. Structure (Camb) 2003; 11: 295–307
   PubMed Web of Science ®Google Scholar
• Antzutkin O N, Balbach J J, Leapman R D, Rizzo N W, Reed J, Tycko R. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA 2000; 97: 13045–13050
   PubMed Web of Science ®Google Scholar
• Ancsin J B. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 2003; 10: 67–79
   PubMed Web of Science ®Google Scholar
• Cohlberg J A, Li J, Uversky V N, Fink A L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 2002; 41: 1502–1511
   PubMed Web of Science ®Google Scholar
• Reilly C E. Crucial role of heparan sulfate proteoglycan (agrin) in beta-amyloid formation in Alzheimer's disease. J Neurol 2000; 247: 663–664
   PubMed Web of Science ®Google Scholar
• McLaurin J, Franklin T, Zhang X, Deng J, Fraser P E. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem 1999; 266: 1101–1110
   PubMedGoogle Scholar
• Kisilevsky R, Lemieux L J, Fraser P E, Kong X, Hultin P G, Szarek W A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143–148
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Szarek W A, Ancsin J, Vohra R, Li Z, Marone S. Novel glycosaminoglycan precursors as antiamyloid agents: Part IV. J Mol Neurosci 2004; 24: 167–172
   PubMed Web of Science ®Google Scholar
• LeVine H, III. Screening for pharmacologic inhibitors of amyloid fibril formation. Methods Enzymol 1999; 309: 467–476
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Ghilardi J R, Felix A M, Lu Y -A, Vinters H V, Mantyh P J, Maggio J E. Ab deposition inhibitor screen using synthetic amyloid. Nat Biotechnol 1997; 15: 258–263
   PubMed Web of Science ®Google Scholar
• Harper J D, Wong S S, Lieber C M, Lansbury P T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997; 4: 119–125
   PubMed Web of Science ®Google Scholar
• Harper J D, Wong S S, Lieber C M, Lansbury P T, Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999; 38: 8972–8980
   PubMed Web of Science ®Google Scholar
• Williams A D, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, Kaleta D T, Cook K D, Wetzel R. Structural properties of Abeta protofibrils stabilized by a small molecule. Proc Natl Acad Sci U S A 2005; 102: 7115–7120
   PubMed Web of Science ®Google Scholar
• Bateman R J, Munsell L Y, Morris J C, Swarm R, Yarasheski K E, Holtzman D M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856–861
   PubMed Web of Science ®Google Scholar
• Cirrito J R, May P C, O'Dell M A, Taylor J W, Parsadanian M, Cramer J W, Audia J E, Nissen J S, Bales K R, Paul S M, DeMattos R B, Holtzman D M. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003; 23: 8844–8853
   PubMed Web of Science ®Google Scholar
• Lemere C A, Spooner E T, LaFrancois J, Malester B, Mori C, Leverone J F, Matsuoka Y, Taylor J W, DeMattos R B, Holtzman D M, Clements J D, Selkoe D J, Duff K E. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003; 14: 10–18
   PubMed Web of Science ®Google Scholar
• Craft D L, Wein L M, Selkoe D J. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma. Bull Math Biol 2002; 64: 1011–1031
   PubMed Web of Science ®Google Scholar
• Kimchi E Y, Kajdasz S, Bacskai B J, Hyman B T. Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy. J Neuropathol Exp Neurol 2001; 60: 274–279
   PubMed Web of Science ®Google Scholar
• Bacskai B J, Kajdasz S T, Christie R H, Carter C, Games D, Seubert P, Schenk D, Hyman B T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7: 369–372
   PubMed Web of Science ®Google Scholar
• Price J C, Klunk W E, Lopresti B J, Lu X, Hoge J A, Ziolko S K, Holt D P, Meltzer C C, Dekosky S T, Mathis C A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528–1547
   PubMed Web of Science ®Google Scholar
• Mathis C A, Klunk W E, Price J C, DeKosky S T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 2005; 62: 196–200
   PubMedGoogle Scholar
• Maier M, Seabrook T J, Lazo N D, Jiang L, Das P, Janus C, Lemere C A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006; 26: 4717–4728
   PubMed Web of Science ®Google Scholar
• Ma Q L, Lim G P, Harris-White M E, Yang F, Ambegaokar S S, Ubeda O J, Glabe C G, Teter B, Frautschy S A, Cole G M. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006; 83: 374–384
   PubMed Web of Science ®Google Scholar
• Head E, Barrett E G, Murphy M P, Das P, Nistor M, Sarsoza F, Glabe C C, Kayed R, Milton S, Vasilevko V, Milgram N W, Agadjanyan M G, Cribbs D H, Cotman C W. Immunization with fibrillar Abeta(1-42) in young and aged canines: antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 2006; 24: 2824–2834
   PubMed Web of Science ®Google Scholar
• Lemere C A, Beierschmitt A, Iglesias M, Spooner E T, Bloom J K, Leverone J F, Zheng J B, Seabrook T J, Louard D, Li D, Selkoe D J, Palmour R M, Ervin F R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165: 283–297
   PubMed Web of Science ®Google Scholar
• Nicoll J A, Wilkinson D, Holmes C, Steart P, Markham H, Weller R O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448–452
   PubMed Web of Science ®Google Scholar
• Agadjanyan M G, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs D H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from {beta}-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580–1586
   PubMed Web of Science ®Google Scholar
• Patton R L, Kalback W M, Esh C L, Kokjohn T A, Van Vickle G D, Luehrs D C, Kuo Y M, Lopez J, Brune D, Ferrer I, Masliah E, Newel A J, Beach T G, Castano E M, Roher A E. Amyloid-{beta} peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048–1063
   PubMed Web of Science ®Google Scholar
• Zlokovic B V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202–208
   PubMed Web of Science ®Google Scholar
• Morgan D. Mechanisms of Abeta plaque clearance following passive Abeta immunization. Neurodegener Dis 2005; 2: 261–266
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004; 75: 742–750
   PubMed Web of Science ®Google Scholar
• Yang F, Lim G P, Begum A N, Ubeda O J, Simmons M R, Ambegaokar S S, Chen P P, Kayed R, Glabe C G, Frautschy S A, Cole G M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892–5901
   PubMed Web of Science ®Google Scholar
• Han Y S, Bastianetto S, Dumont Y, Quirion R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 2006; 318: 238–245
   PubMed Web of Science ®Google Scholar
• Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002; 137: 676–682
   PubMed Web of Science ®Google Scholar
• Nichols M R, Moss M A, Reed D K, Lin W L, Mukhopadhyay R, Hoh J H, Rosenberry T L. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 2002; 41: 6115–6127
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Jennings J M, Vinters H V, Ghilardi J R, Lee J P, Mantyh P W, Maggio J E. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 2000; 39: 6288–6295
   PubMed Web of Science ®Google Scholar
• Berthelier V, Wetzel R. Screening for modulators of aggregation with a microplate elongation assay. Methods Enzymol 2006; 413: 313–325
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Mantyh P W, Maggio J E. Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. Methods Enzymol 1999; 309: 350–374
   PubMed Web of Science ®Google Scholar
• Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol 1999; 309: 256–274
   PubMed Web of Science ®Google Scholar
• Williams A D, Portelius E, Kheterpal I, Guo J T, Cook K D, Xu Y, Wetzel R. Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 2004; 335: 833–842
   PubMed Web of Science ®Google Scholar
• Findeis M A, Musso G M, Arico Muendel C C, Benjamin H W, Hundal A M, Lee J J, Chin J, Kelley M, Wakefield J, Hayward N J, Molineaux S M. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 1999; 38: 6791–6800
   PubMed Web of Science ®Google Scholar
• Sciarretta K L, Gordon D J, Meredith S C. Peptide-based inhibitors of amyloid assembly. Methods Enzymol 2006; 413: 273–312
   PubMed Web of Science ®Google Scholar
• Kokkoni N, Stott K, Amijee H, Mason J M, Doig A J. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 2006; 45: 9906–9918
   PubMed Web of Science ®Google Scholar
• Barta N S, Bigge C F. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives. 2005, Patent Appl. No. 6,949,575
   Google Scholar
• Rzepecki P, Gallmeier H, Geib N, Cernovska K, Konig B, Schrader T. New heterocyclic beta-sheet ligands with peptidic recognition elements. J Org Chem 2004; 69: 5168–5178
   PubMed Web of Science ®Google Scholar
• Rzepecki P, Nagel-Steger L, Feuerstein S, Linne U, Molt O, Zadmard R, Aschermann K, Wehner M, Schrader T, Riesner D. Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands. J Biol Chem 2004; 279: 47497–47505
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. Anti-parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int 2006; 48: 275–285
   PubMed Web of Science ®Google Scholar
• Soto C, Kindy M S, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672–680
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. Preformed beta-amyloid fibrils are destabilized by coenzyme Q(10) in vitro. Biochem Biophys Res Commun 2005; 330: 111–116
   PubMed Web of Science ®Google Scholar
• Lee K H, Shin B H, Shin K J, Kim D J, Yu J. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). Biochem Biophys Res Commun 2005; 328: 816–823
   PubMed Web of Science ®Google Scholar
• Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 2005; 336: 444–449
   PubMed Web of Science ®Google Scholar
• Bose M, Gestwicki J E, Devasthali V, Crabtree G R, Graef I A. ‘Nature-inspired’ drug-protein complexes as inhibitors of Abeta aggregation. Biochem Soc Trans 2005; 33: 543–547
   PubMed Web of Science ®Google Scholar
• Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006; 45: 4727–4735
   PubMed Web of Science ®Google Scholar
• Pappolla M, Bozner P, Soto C, Shao H, Robakis N K, Zagorski M, Frangione B, Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185–7188
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry 2002; 52: 880–886
   PubMed Web of Science ®Google Scholar
• Zeng H, Zhang Y, Peng L, Shao H, Menon N K, Yang J, Salomon A R, Freidland R P, Zagorski M G. Nicotine and amyloid formation. Biol Psychiatry 2001; 49: 248–257
   PubMed Web of Science ®Google Scholar
• Moore S A, Huckerby T N, Gibson G L, Fullwood N J, Turnbull S, Tabner B J, El-Agnaf O M, Allsop D. Both the d-(+) and l-(−) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. Biochemistry 2004; 43: 819–826
   PubMed Web of Science ®Google Scholar
• Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1998; 37: 17882–17889
   PubMed Web of Science ®Google Scholar
• Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005; 49: 1088–1099
   PubMed Web of Science ®Google Scholar
• Torok M, Abid M, Mhadgut S C, Torok B. Organofluorine inhibitors of amyloid fibrillogenesis. Biochemistry 2006; 45: 5377–5383
   PubMed Web of Science ®Google Scholar
• Augelli-Szafran C E, Sakkab A T, Yasunaga T. Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of Alzheimer's disease and disorders related to amyloidosis. 2004, Patent Appl. No. 20040180943
   Google Scholar
• Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005; 280: 7614–7623
   PubMed Web of Science ®Google Scholar
• Augelli-Szafran C E, Lai Y, Yasunaga T. Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of Alzheimer's disease and disorders related to amyloidosis. 2002, Patent Appl. No. 20020143012
   Google Scholar
• Lin S J, Shiao Y J, Chi C W, Yang L M. Abeta aggregation inhibitors. Part 1: Synthesis and biological activity of phenylazo benzenesulfonamides. Bioorg Med Chem Lett 2004; 14: 1173–1176
   PubMed Web of Science ®Google Scholar
• Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67: 27–37
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim Biophys Acta 2004; 1690: 193–202
   PubMed Web of Science ®Google Scholar
• Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 1994; 204: 76–83
   PubMed Web of Science ®Google Scholar
• Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 1996; 271: 6839–6844
   PubMed Web of Science ®Google Scholar
• Augelli-Szafran C E, Glase S A, Purchase T S. Method of imaging amyloid deposits using substituted rhodanine derivatives. 2004, Patent Appl. No. 20040197268
   Google Scholar
• Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001; 487: 404–407
   PubMed Web of Science ®Google Scholar
• Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189: 380–392
   PubMed Web of Science ®Google Scholar
• Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril- destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172–181
   PubMed Web of Science ®Google Scholar
• McLaurin J, Golomb R, Jurewicz A, Antel J P, Fraser P E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem 2000; 275: 18495–18502
   PubMed Web of Science ®Google Scholar
• McLaurin J, Kierstead M E, Brown M E, Hawkes C A, Lambermon M H, Phinney A L, Darabie A A, Cousins J E, French J E, Lan M F, Chen F, Wong S S, Mount H T, Fraser P E, Westaway D, George-Hyslop P S. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12: 808–808
   Web of Science ®Google Scholar
• De Felice F G, Vieira M N, Saraiva L M, Figueroa-Villar J D, Garcia-Abreu J, Liu R, Chang L, Klein W L, Ferreira S T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. Faseb J 2004; 18: 1366–1372
   PubMed Web of Science ®Google Scholar
• Maezawa I, Hong H S, Wu H C, Battina S K, Rana S, Iwamoto T, Radke G A, Pettersson E, Martin G M, Hua D H, Jin L W. A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 2006; 98: 57–67
   PubMed Web of Science ®Google Scholar